Typewriter secures $56M for non-viral gene therapy platform
Gene therapy startup Typewriter has raised a $56 million Series A to advance its non-viral delivery method. The approach avoids viral vectors, which have faced scrutiny over safety concerns. The funding will support further development of its platform.
Sources: msn.com
“The raise underscores growing investor interest in alternatives to viral vectors, as safety and scalability concerns persist in gene therapy.”
Read the original reporting
This is a short summary. The outlets below did the reporting.
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.